Response to Radioiodine Therapy for Thyrotoxicosis: Disparate Outcomes for an Indigenous Population
Table 2
Baseline data by ethnicity.
Non-Māori ()
Māori ()
Age
142
55 (52.6, 57.6)
71
50.4 (47.7, 53.1)
0.0132
Gender
F
142
116 (81.7%)
71
61 (85.9%)
0.438
M
26 (18.3%)
10 (14.1%)
Diagnosis
GD
142
98 (69.0%)
71
36 (50.7%)
0.011
TMNG
39 (27.5%)
34 (47.9%)
STA
5 (3.5%)
1 (1.4%)
Weight (kg)
133
73.7 (52.2, 118.3)
67
81.4 (55.1, 118.1)
0.0698
Ophthalmopathy
Nil
96
71 (74.0%)
36
25 (69.4%)
0.814
Mild
18 (18.8%)
7 (19.4%)
Mod.
4 (4.2%)
3 (8.3%)
Sev.
3 (3.0%)
1 (2.8%)
T4 at presentation
133
28 (12, 61)
68
30 (11, 74)
0.2461
Pretreatment ATD
142
118 (83.1%)
71
66 (93.0%)
0.048
Length of ATD (wks)
117
44 (9, 374)
66
52 (14, 504)
0.4837
Posttreatment ATD
117
42 (35.9%)
65
28 (43.08%)
0.34
Follow-up length (wks)
142
944 (428, 1459)
71
791 (432, 1481)
0.1361
ATD: antithyroid medication; F: female; M: male; GD: Graves’s disease; TMNG: toxic multinodular goitre; STA: solitary toxic adenoma; Mod.: moderate eye disease; Sev.: severe eye disease. Continuous variables are expressed as mean (95% confidence intervals) or median (5th, 95th percentile) according to their distribution. Categorical variables are expressed as number (percentage).
